By: ChinaBio® Today
March 22, 2013 at 07:14 AM EDT
BGI and H3 Biomedicine to Sequence Pre-Clinical Cancer Models
BGI-Shenzhen and H3 Biomedicine of Cambridge, MA have agreed to develop genomic sequencing data from pre-clinical cancer models. The research is designed to identify and validate recurrent gene mutations that are potential targets for drug therapies. BGI and H3 will share their findings with the global research community after the data analysis is completed. Earlier this week, ChinaBio® Today published an interview with Jun Wang, PhD, the CEO of BGI. Dr. Wang declared that pure science was always the motivating force behind the company’s alliances. More details.... Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here